ARTICLE | Company News
Stedesa review extended
January 28, 2010 1:09 AM UTC
FDA extended by three months from Jan. 30 to April 30 the PDUFA date for an NDA from Sepracor Inc. for Stedesa eslicarbazepine as adjunctive therapy to treat partial-onset seizures in adults with epil...